Recap: DermTech Q1 Earnings

Shares of DermTech DMTK rose in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 3.77% over the past year to ($0.55), which missed the estimate of ($0.42).

Revenue of $2,524,000 up by 62.11% year over year, which beat the estimate of $2,110,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 13, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/khfwd4vu

Recent Stock Performance

52-week high: $84.49

Company's 52-week low was at $9.64

Price action over last quarter: down 40.66%

Company Profile

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!